Keyword: Boehringer Ingelheim
NBE will use the money to start testing anti-ROR1 antibody-drug conjugate NBE-002 in solid tumor patients.
Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity.
Gilead is committing to milestones that could exceed $400 million to snag exclusive rights to two technologies in the indications.
U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials.
Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.
BI 409306 failed to show superiority over placebo in cognition across a midphase program that enrolled 457 patients with early signs of Alzheimer’s.
Bob Hugin retires from Celgene, Voyager founder steps down as CEO, Boehringer named new U.S. chief to replace retiring Fonteyne.
Sanofi’s €45-a-share cash bid enabled it to leapfrog Novo Nordisk in the race to buy Ablynx and land its second big-ticket takeover of the month.